Berry GenomicsLtd Past Earnings Performance
Past criteria checks 0/6
Berry GenomicsLtd's earnings have been declining at an average annual rate of -69.4%, while the Biotechs industry saw earnings growing at 3.1% annually. Revenues have been declining at an average rate of 7.2% per year.
Key information
-69.4%
Earnings growth rate
-69.1%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -7.2% |
| Return on equity | -16.7% |
| Net Margin | -28.3% |
| Next Earnings Update | 29 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Berry GenomicsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,142 | -323 | 548 | 103 |
| 31 Mar 24 | 1,151 | -398 | 561 | 110 |
| 31 Dec 23 | 1,151 | -427 | 567 | 110 |
| 30 Sep 23 | 1,180 | -368 | 575 | 102 |
| 30 Jun 23 | 1,248 | -325 | 554 | 103 |
| 31 Mar 23 | 1,335 | -258 | 566 | 101 |
| 01 Jan 23 | 1,368 | -249 | 561 | 107 |
| 30 Sep 22 | 1,363 | -155 | 526 | 114 |
| 30 Jun 22 | 1,369 | -161 | 530 | 118 |
| 31 Mar 22 | 1,401 | -144 | 527 | 123 |
| 01 Jan 22 | 1,422 | -111 | 510 | 128 |
| 30 Sep 21 | 1,565 | 88 | 482 | 128 |
| 30 Jun 21 | 1,553 | 124 | 461 | 130 |
| 31 Mar 21 | 1,505 | 170 | 442 | 127 |
| 31 Dec 20 | 1,540 | 211 | 435 | 126 |
| 30 Sep 20 | 1,531 | 228 | 404 | 127 |
| 30 Jun 20 | 1,585 | 258 | 398 | 122 |
| 31 Mar 20 | 1,655 | 285 | 425 | 133 |
| 31 Dec 19 | 1,618 | 391 | 414 | 120 |
| 30 Sep 19 | 1,586 | 342 | 426 | 118 |
| 30 Jun 19 | 1,549 | 372 | 422 | 115 |
| 31 Mar 19 | 1,475 | 370 | 369 | 108 |
| 31 Dec 18 | 1,440 | 268 | 381 | 91 |
| 30 Sep 18 | 1,387 | 312 | 351 | 63 |
| 30 Jun 18 | 1,295 | 288 | 344 | 43 |
| 31 Mar 18 | 1,244 | 260 | 394 | 34 |
| 31 Dec 17 | 1,171 | 233 | 390 | 34 |
| 30 Sep 17 | 1,089 | 219 | 385 | 26 |
| 30 Jun 17 | 1,057 | 188 | 405 | 20 |
| 31 Mar 17 | 954 | 163 | 377 | 0 |
| 31 Dec 16 | 922 | 151 | 382 | 0 |
| 31 Dec 15 | 446 | 44 | 217 | 0 |
| 31 Dec 14 | 334 | 46 | 188 | 0 |
| 30 Sep 14 | 276 | -7 | 42 | 0 |
| 30 Jun 14 | 271 | -8 | 40 | 0 |
| 31 Mar 14 | 248 | -6 | 36 | 0 |
| 31 Dec 13 | 262 | -6 | 36 | 0 |
Quality Earnings: 000710 is currently unprofitable.
Growing Profit Margin: 000710 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000710 is unprofitable, and losses have increased over the past 5 years at a rate of 69.4% per year.
Accelerating Growth: Unable to compare 000710's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000710 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (10.1%).
Return on Equity
High ROE: 000710 has a negative Return on Equity (-16.74%), as it is currently unprofitable.